CA
TNGX icon

Clearstead Advisors’s Tango Therapeutics TNGX Stock Holding History

Clearstead Advisors’s Portfolio TNGX Stock Details TNGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$942 Hold
45
– – ﹤0.01% 2053
2025
Q4 		$399 Buy
+45
New +$388 ﹤0.01% 2334

Other funds holding TNGX

RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
BCM
Boxer Capital Management San Diego, California $762M AUM 1,125.36% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
NI
Nextech Invest Zurich, Switzerland $1.42B AUM 304.47% 1-Year Est. Return
TGI
TRV GP IV Boston, Massachusetts $267M AUM 965.83% 1-Year Est. Return

Clearstead Advisors's TNGX Position: Q1 2026 in Review

Clearstead Advisors held its Tango Therapeutics (TNGX) position steady in Q1 2026 at 45 shares worth $942. The position accounts for ﹤0.01% of the portfolio, ranked #2053.

Clearstead Advisors first reported a position in TNGX in Q4 2025 and has held it in 2 quarters since. 194 funds tracked by Wall St. Rank hold TNGX as of Q1 2026.

  • Clearstead Advisors held 45 shares of Tango Therapeutics worth $942 as of Q1 2026.
  • Clearstead Advisors left its Tango Therapeutics share count unchanged in Q1 2026.
  • Tango Therapeutics made up ﹤0.01% of Clearstead Advisors's portfolio in Q1 2026, its #2053 holding.
  • Clearstead Advisors first reported a position in Tango Therapeutics in Q4 2025 and has held it in 2 quarters since.
  • 194 funds tracked by Wall St. Rank held Tango Therapeutics as of Q1 2026.

Based on Clearstead Advisors's 13F filing for Q1 2026, filed 6 May 2026.